Concepedia

Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)

Rafael Rosell, B. Massuti Sureda, Carlota Costa, M.A. Molina, Ana Giménez‐Capitán, Niki Karachaliou, Jia Wei, A. Vergnenègre, Petros Giannikopoulos, Craig H. Mermel,

Annals of Oncology · 2012 · 17 citations · 0 references

DOI

Concepts